Given the inherent heterogeneity of ER+ breast cancer, the relapse to the ER− tumor subtype post-endocrine therapy, and the enumeration of CSCs in driving tumor progression and disease resistance, there is less evidence connecting the influence of hormone receptors and CSC-mediated cell state transitions. The gene discussed is ESR1; the disease is neoplasm.